EASi-HF

a Phase III double-blind, randomised, parallel group superority trial to evaluate efficacy and safety of the combined used of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in patients with heart failure NYHA II-IV and LVEF > 40%